Gujarat Inject (Kerala) Ltd.
Snapshot View

7.32 -0.38 ▼-4.9%

27 January 2023, 12:11:00 PM
Volume: 2,652

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.gujaratinject.com
Market Cap 3.59 Cr.
Enterprise Value(EV) 4.60 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 0.13 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 57.84 Trailing Twelve Months Ending 2022-09
Industry PE 33.61 Trailing Twelve Months Ending 2022-09
Book Value / Share -1.70 Trailing Twelve Months Ending 2022-09
Price to Book Value -4.30 Calculated using Price: 7.32
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 0.49 Cr. 4,899,000 Shares
FaceValue 10
Company Profile
Gujarat Inject (Kerala) (GKIL) was incorporated on January 7, 1991 and obtained certificate for commencement of business on February 14, 1991. The company has been jointly promoted by the Kerala State Industrial Development Corporation (KSIDC), a wholly owned subsidiary of Government of Kerala undertaking and Gujarat Inject (GIL) and its associates. The company has received SIA registration to manufacture intravenous solutions at puddussey east, kanjikode, in palghat district in Kerala.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-4.94%
1 Week
-13.48%
1 Month
-36.79%
3 Month
+5.93%
6 Month
+22.20%
1 Year
2 Year
5 Year
10 Year
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%)
Return on Capital Employed (%)
Return on Assets (%) -1.68 -1.84 1,373.74 6.93 -102.49 -30.20 1.57 -664.44 5.37

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds -3 -3 -1 -1 -1 -1 -1 -1 -1 -1
Non Curr. Liab. 0 0 0 0 0 0 0 0 0
Curr. Liab. 3 3 1 0 0 0 0 0 1 0
Minority Int.
Equity & Liab. 0 0 0 0 0 0 0 0 0 0
Non Curr. Assets 0 0
Curr. Assets 0 0 0 0 0 0 0 0 0 0
Misc. Exp. not W/O
Total Assets 0 0 0 0 0 0 0 0 0 0

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 0 2 0 0 0
Other Income 0 0 0 0 0 0
Total Income 0 2 0 0 0 0 0 1
Total Expenditure 0 -2 0 0 0 0 0 0
PBIDT 0 0 0 0 0
Interest
Depreciation
Taxation 0
Exceptional Items 2
PAT 2 0 0 0 0 0
Adjusted EPS 0 0 5 0 0 0 0 0

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 0
Cash Fr. Inv.
Cash Fr. Finan. 0
Net Change 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details >>

9 Qtrs 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%)
Promoter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Public 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Fri, 30 Dec 2022
Closure of Trading Window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and Companys Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities this is to inform that the trading window for dealing in Equity Shares of the Company by the Insiders covered under Companys Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities will be closed from Sunday January 01 2023 till 48 hours after the declaration and publication of Financial Results for the quarter ended December 31 2022. The above closure has been intimated based on BSE Circular no. LIST /COMP/01/2019 20 dated April 2 2019 - Clarification regarding trading restriction period and the Securities and Exchange Board of India (Prohibition of Insider Trading) (Second Amendment) Regulations 2019.
Thu, 10 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On November 10 2022 In Terms Of Second ProvisoTo Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
In reference to captioned subject we hereby inform you that the Board of Directors of the Company intheir Board Meeting held on today i.e. on November 10 2022 at the Administrative Office of the Companywhich was commenced at 04:45 PM and concluded at 05:00 PM has apart from other businesses considered approved and taken on record the Unaudited Financial Result of the Company for the quarter ended onSeptember 30 2022 along with Limited Review Report.
Thu, 10 Nov 2022
Submission Of Unaudited Financial Result Of The Company For The Quarter Ended On September30 2022 Along With Limited Review Report.
In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations andDisclosure Requirements) Regulations 2015 we are hereby submitting the followings:1. Unaudited Financial Results for the quarter ended on September 30 2022;2. Limited Review Report.

Technical Scans View Details >>

Wed, 25 Jan 2023
Opening at Low Opening at Low
Closing Below Previous Low Closing Below Previous Low
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Below Last Week Low Close Below Last Week Low
High Decrease in 1 Month High Decrease in 1 Month

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,518.84 1,045.00 +0.5%
Divi's Laboratories Ltd. 88,552.35 3,362.75 +0.8%
Cipla Ltd. 83,862.25 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. 69,879.98 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. 60,777.77 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. 52,497.96 1,531.20 -1.6%
Abbott India Ltd. 45,101.64 21,213.70 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.79 1,045.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-09 29.71 3,362.75 +0.8%
Cipla Ltd. Consolidated 2022-09 32.68 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 22.47 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.39 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 65.87 1,531.20 -1.6%
Abbott India Ltd. Standalone 2022-09 51.15 21,213.70 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,045.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-09 7.33 3,362.75 +0.8%
Cipla Ltd. Consolidated 2022-09 3.83 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 3.36 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.15 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 8.62 1,531.20 -1.6%
Abbott India Ltd. Standalone 2022-09 16.62 21,213.70 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,045.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,362.75 +0.8%
Cipla Ltd. Consolidated 2022-03 0.04 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,531.20 -1.6%
Abbott India Ltd. Standalone 2022-03 0.00 21,213.70 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,045.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,362.75 +0.8%
Cipla Ltd. Consolidated 2022-03 13.10 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,531.20 -1.6%
Abbott India Ltd. Standalone 2022-03 29.95 21,213.70 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,045.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,362.75 +0.8%
Cipla Ltd. Consolidated 2022-03 13.10 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,531.20 -1.6%
Abbott India Ltd. Standalone 2022-03 29.95 21,213.70 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,045.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,362.75 +0.8%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,531.20 -1.6%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,213.70 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,045.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,362.75 +0.8%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,048.90 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,322.85 +2.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,225.70 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,531.20 -1.6%
Abbott India Ltd. Standalone 2022-03 798.70 21,213.70 -0.3%

FAQ's On Gujarat Inject (Kerala) Ltd.

What is Guj. Inject (Kerala) share price?

Can I buy Guj. Inject (Kerala) shares now?

What is the Market Cap of Guj. Inject (Kerala)?

What are the key metrics to analyse Guj. Inject (Kerala)?

What is the 52 Week High and Low of Guj. Inject (Kerala)?

What is the trend of Guj. Inject (Kerala) share price?